New Alzheimer’s drug trial seen as ‘potentially very important’

Positive results from an Alzheimer’s trial by Eli Lilly are seen as a very important step in the battle to fight the fatal disease, but questions remain about whether it will be covered by Medicare.

Eli Lilly’s LLY positive Phase 3 trial showed that the drug donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease, and met its primary and secondary goals. 

“The…